BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Roland CL, Yang AD, Katz MH, Chatterjee D, Wang H, Lin H, Vauthey JN, Pisters PW, Varadhachary GR, Wolff RA, Crane CH, Lee JE, Fleming JB. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer. Ann Surg Oncol. 2015;22:1168-1175. [PMID: 25352267 DOI: 10.1245/s10434-014-4192-6] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Tao L, Zhang L, Peng Y, Tao M, Li G, Xiu D, Yuan C, Ma C, Jiang B. Preoperative neutrophil-to-lymphocyte ratio and tumor-related factors to predict lymph node metastasis in patients with pancreatic ductal adenocarcinoma (PDAC). Oncotarget 2016;7:74314-24. [PMID: 27494847 DOI: 10.18632/oncotarget.11031] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
2 Casolino R, Braconi C, Malleo G, Paiella S, Bassi C, Milella M, Dreyer SB, Froeling FEM, Chang DK, Biankin AV, Golan T. Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Ann Oncol 2021;32:183-96. [PMID: 33248227 DOI: 10.1016/j.annonc.2020.11.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
3 Nejati R, Goldstein JB, Halperin DM, Wang H, Hejazi N, Rashid A, Katz MH, Lee JE, Fleming JB, Rodriguez-Canales J, Blando J, Wistuba II, Maitra A, Wolff RA, Varadhachary GR, Wang H. Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy. Pancreas 2017;46:1180-7. [PMID: 28902789 DOI: 10.1097/MPA.0000000000000914] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
4 Lee SM, Katz MH, Liu L, Sundar M, Wang H, Varadhachary GR, Wolff RA, Lee JE, Maitra A, Fleming JB, Rashid A, Wang H. Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival. Am J Surg Pathol 2016;40:1653-60. [PMID: 27631521 DOI: 10.1097/PAS.0000000000000738] [Cited by in Crossref: 56] [Cited by in F6Publishing: 18] [Article Influence: 11.2] [Reference Citation Analysis]
5 Wolff RA. Adjuvant or Neoadjuvant Therapy in the Treatment in Pancreatic Malignancies: Where Are We? Surg Clin North Am 2018;98:95-111. [PMID: 29191281 DOI: 10.1016/j.suc.2017.09.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
6 Pu N, Gao S, Beckman R, Ding D, Wright M, Chen Z, Zhu Y, Hu H, Yin L, Beckman M, Thompson E, Hruban RH, Cameron JL, Gage MM, Lafaro KJ, Burns WR, Wolfgang CL, He J, Yu J, Burkhart RA. Defining a minimum number of examined lymph nodes improves the prognostic value of lymphadenectomy in pancreas ductal adenocarcinoma. HPB (Oxford) 2021;23:575-86. [PMID: 32900612 DOI: 10.1016/j.hpb.2020.08.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sahni S, Nahm C, Krisp C, Molloy MP, Mehta S, Maloney S, Itchins M, Pavlakis N, Clarke S, Chan D, Gill AJ, Howell VM, Samra J, Mittal A. Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy. Front Oncol 2020;10:237. [PMID: 32195182 DOI: 10.3389/fonc.2020.00237] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
8 Nishiwada S, Sho M, Cui Y, Yamamura K, Akahori T, Nakagawa K, Nagai M, Nakamura K, Takagi T, Ikeda N, Li W, Baba H, Goel A. A gene expression signature for predicting response to neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. Int J Cancer 2021;148:769-79. [PMID: 32895958 DOI: 10.1002/ijc.33284] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Zhang Y, Huang ZX, Song B. Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma. World J Gastroenterol 2021; 27(22): 3037-3049 [PMID: 34168406 DOI: 10.3748/wjg.v27.i22.3037] [Reference Citation Analysis]
10 Zheng ZJ, Wang MJ, Tan CL, Chen YH, Ping J, Liu XB. Prognostic impact of lymph node status in patients after total pancreatectomy for pancreatic ductal adenocarcinoma: A strobe-compliant study. Medicine (Baltimore) 2020;99:e19327. [PMID: 32080152 DOI: 10.1097/MD.0000000000019327] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Mahipal A, Frakes J, Hoffe S, Kim R. Management of borderline resectable pancreatic cancer. World J Gastrointest Oncol 2015; 7(10): 241-249 [PMID: 26483878 DOI: 10.4251/wjgo.v7.i10.241] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
12 Ren X, Wei X, Ding Y, Qi F, Zhang Y, Hu X, Qin C, Li X. Comparison of neoadjuvant therapy and upfront surgery in resectable pancreatic cancer: a meta-analysis and systematic review. Onco Targets Ther 2019;12:733-44. [PMID: 30774360 DOI: 10.2147/OTT.S190810] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Drake JA, Stiles ZE, Behrman SW, Glazer ES, Deneve JL, Somer BG, Vanderwalde NA, Dickson PV. The utilization and impact of adjuvant therapy following neoadjuvant therapy and resection of pancreatic adenocarcinoma: does more really matter? HPB (Oxford) 2020;22:1530-41. [PMID: 32209323 DOI: 10.1016/j.hpb.2020.02.011] [Reference Citation Analysis]
14 Macedo FI, Picado O, Hosein PJ, Dudeja V, Franceschi D, Mesquita-Neto JW, Yakoub D, Merchant NB. Does Neoadjuvant Chemotherapy Change the Role of Regional Lymphadenectomy in Pancreatic Cancer Survival? Pancreas 2019;48:823-31. [PMID: 31210664 DOI: 10.1097/MPA.0000000000001339] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
15 Rangarajan K, Pucher PH, Armstrong T, Bateman A, Hamady Z. Systemic neoadjuvant chemotherapy in modern pancreatic cancer treatment: a systematic review and meta-analysis. Ann R Coll Surg Engl. 2019;101:453-462. [PMID: 31304767 DOI: 10.1308/rcsann.2019.0060] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
16 Kurahara H, Maemura K, Mataki Y, Sakoda M, Iino S, Kawasaki Y, Arigami T, Mori S, Kijima Y, Ueno S, Shinchi H, Natsugoe S. A Therapeutic Strategy for Resectable Pancreatic Cancer Based on Risk Factors of Early Recurrence. Pancreas 2018;47:753-8. [PMID: 29771771 DOI: 10.1097/MPA.0000000000001066] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
17 Joliat GR, Allemann P, Labgaa I, Sulzer J, Vrochides D, Zerbi A, Nappo G, Perinel J, Adham M, Nentwich MF, Izbicki JR, Demartines N, Schäfer M. Prognostic value of positive histological margins in patients with pancreatic head ductal adenocarcinoma and lymph node involvement: an international multicentric study. HPB (Oxford) 2021;23:379-86. [PMID: 32782224 DOI: 10.1016/j.hpb.2020.07.008] [Reference Citation Analysis]
18 Bradley A, Van Der Meer R. Neoadjuvant therapy versus upfront surgery for potentially resectable pancreatic cancer: A Markov decision analysis. PLoS One 2019;14:e0212805. [PMID: 30817807 DOI: 10.1371/journal.pone.0212805] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
19 Bradley A, Van Der Meer R. Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis. Sci Rep 2019;9:4354. [PMID: 30867522 DOI: 10.1038/s41598-019-40951-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
20 Swords DS, Francis SR, Lloyd S, Garrido-laguna I, Mulvihill SJ, Gruhl JD, Christensen MC, Stoddard GJ, Firpo MA, Scaife CL. Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative Chemotherapy. J Gastrointest Surg 2019;23:1401-13. [DOI: 10.1007/s11605-018-3953-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
21 Yang L, Bai Y, Li Q, Chen J, Liu F, Weng X, Xu F. Analysis of the Curative Effect of Neoadjuvant Therapy on Pancreatic Cancer. Front Oncol 2021;11:695645. [PMID: 34485131 DOI: 10.3389/fonc.2021.695645] [Reference Citation Analysis]
22 Sahakyan MA, Kim SC, Kleive D, Kazaryan AM, Song KB, Ignjatovic D, Buanes T, Røsok BI, Labori KJ, Edwin B. Laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma: Long-term oncologic outcomes after standard resection. Surgery 2017;162:802-11. [PMID: 28756944 DOI: 10.1016/j.surg.2017.06.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
23 Chen YR, Wang MQ, Li YT, Li P, Ouyang SS, Xu HW, Zhu SL. Prognostic performance of different lymph node classification systems in young gastric cancer. J Gastrointest Oncol 2021;12:1285-300. [PMID: 34532088 DOI: 10.21037/jgo-21-185] [Reference Citation Analysis]
24 Ye M, Zhang Q, Chen Y, Fu Q, Li X, Bai X, Liang T. Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis. HPB (Oxford) 2020;22:821-32. [PMID: 32001139 DOI: 10.1016/j.hpb.2020.01.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
25 Katz MHG. Should Fear of Adverse Events Influence the Decision to Administer Preoperative Therapy to Patients with Pancreatic Cancer? Ann Surg Oncol 2018;25:588-90. [DOI: 10.1245/s10434-017-6302-8] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
26 Schorn S, Demir IE, Samm N, Scheufele F, Calavrezos L, Sargut M, Schirren RM, Friess H, Ceyhan GO. Meta-analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma. BJS Open 2018;2:52-61. [PMID: 29951629 DOI: 10.1002/bjs5.46] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
27 Schorn S, Demir IE, Reyes CM, Saricaoglu C, Samm N, Schirren R, Tieftrunk E, Hartmann D, Friess H, Ceyhan GO. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis. Cancer Treat Rev 2017;55:96-106. [PMID: 28342938 DOI: 10.1016/j.ctrv.2017.03.003] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 9.8] [Reference Citation Analysis]
28 Combs SE. Individualized radiotherapy (iRT) concepts for locally advanced pancreatic cancer (LAPC): indications and prognostic factors. Langenbecks Arch Surg 2015;400:749-56. [DOI: 10.1007/s00423-015-1309-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
29 Bolton NM, Maerz AH, Brown RE, Bansal M, Bolton JS, Conway WC. Multiagent neoadjuvant chemotherapy and tumor response are associated with improved survival in pancreatic cancer. HPB 2019;21:413-8. [DOI: 10.1016/j.hpb.2018.08.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
30 Xu X, Wu Q, Wang Z, Zheng S, Ge K, Jia C. Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer. Clin Exp Med 2019;19:149-57. [PMID: 30498929 DOI: 10.1007/s10238-018-0540-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
31 Cloyd JM, Wang H, Overman M, Zhao J, Denbo J, Prakash L, Kim MP, Shroff R, Javle M, Varadhachary GR, Fogelman D, Wolff RA, Koay EJ, Das P, Maitra A, Aloia TA, Vauthey JN, Fleming JB, Lee JE, Katz MHG. Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. Ann Surg Oncol. 2017;24:2031-2039. [PMID: 28124275 DOI: 10.1245/s10434-017-5777-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
32 Wang S, Shi H, Yang F, Teng X, Jiang B. The value of 18F-FDG PET/CT and carbohydrate antigen 19-9 in predicting lymph node micrometastases of pancreatic cancer. Abdom Radiol (NY) 2019;44:4057-62. [PMID: 31570958 DOI: 10.1007/s00261-019-02248-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
33 Pan L, Fang J, Tong C, Chen M, Zhang B, Juengpanich S, Wang Y, Cai X. Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis. World J Surg Oncol. 2019;18:1. [PMID: 31892339 DOI: 10.1186/s12957-019-1767-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 6.7] [Reference Citation Analysis]
34 Choi SH, Kim HY, Hwang HK, Kang CM, Lee WJ. Oncologic Impact of Local Recurrence in Resected Pancreatic Cancer and Topographic Preference in Local Recurrence Patterns According to Tumor Location. Pancreas 2020;49:1290-6. [PMID: 33122516 DOI: 10.1097/MPA.0000000000001679] [Reference Citation Analysis]
35 Roland CL, Katz MH, Tzeng CW, Lin H, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Vauthey JN, Crane CH, Lee JE, Fleming JB. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. Ann Surg Oncol. 2015;22 Suppl 3:S1221-S1228. [PMID: 26350371 DOI: 10.1245/s10434-015-4854-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
36 Christians KK, Heimler JW, George B, Ritch PS, Erickson BA, Johnston F, Tolat PP, Foley WD, Evans DB, Tsai S. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Surgery. 2016;159:893-900. [PMID: 26602840 DOI: 10.1016/j.surg.2015.09.018] [Cited by in Crossref: 86] [Cited by in F6Publishing: 70] [Article Influence: 14.3] [Reference Citation Analysis]
37 Bi L, Liu Y, Xu J, Wang X, Zhang T, Li K, Duan M, Huang C, Meng X, Huang Z. A CT-Based Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Periampullary Carcinomas. Front Oncol 2021;11:632176. [PMID: 34395237 DOI: 10.3389/fonc.2021.632176] [Reference Citation Analysis]
38 Rahman SH, Urquhart R, Molinari M. Neoadjuvant therapy for resectable pancreatic cancer. World J Gastrointest Oncol 2017; 9(12): 457-465 [PMID: 29290916 DOI: 10.4251/wjgo.v9.i12.457] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
39 Rempel V, Safi A, Drebber U, Nickenig H, Neugebauer J, Zöller J, Kreppel M. The prognostic relevance of lymph node ratio in patients with oral squamous cell carcinoma treated with neoadjuvant therapy regimen and radical surgery. Journal of Cranio-Maxillofacial Surgery 2018;46:1659-63. [DOI: 10.1016/j.jcms.2018.05.053] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
40 Oppliger FA, Prakash LR, Newhook TE, Chiang YJ, Ikoma N, Maxwell JE, Kim MP, Vauthey JN, Lee JE, Katz MH, Tzeng CD. AJCC 8th edition pathologic nodal staging of resected pancreatic adenocarcinoma predicts survival regardless of treatment sequencing. Surg Oncol 2021;40:101673. [PMID: 34894620 DOI: 10.1016/j.suronc.2021.101673] [Reference Citation Analysis]
41 Nishiwada S, Sho M, Banwait JK, Yamamura K, Akahori T, Nakamura K, Baba H, Goel A. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases. Gastroenterology 2020;159:562-74. [PMID: 32376411 DOI: 10.1053/j.gastro.2020.04.057] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
42 Malleo G, Maggino L, Nobile S, Casciani F, Cacciatori N, Paiella S, Luchini C, Rusev B, Capelli P, Marchegiani G, Bassi C, Salvia R. Reappraisal of nodal staging and study of lymph node station involvement in distal pancreatectomy for body-tail pancreatic ductal adenocarcinoma. Eur J Surg Oncol 2020;46:1734-41. [PMID: 32327367 DOI: 10.1016/j.ejso.2020.04.006] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 O'Rourke MB, Sahni S, Samra J, Mittal A, Molloy MP. Data independent acquisition of plasma biomarkers of response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma. J Proteomics 2021;231:103998. [PMID: 33027703 DOI: 10.1016/j.jprot.2020.103998] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Li K, Yao Q, Xiao J, Li M, Yang J, Hou W, Du M, Chen K, Qu Y, Li L, Li J, Wang X, Luo H, Yang J, Zhang Z, Chen W. Contrast-enhanced CT radiomics for predicting lymph node metastasis in pancreatic ductal adenocarcinoma: a pilot study. Cancer Imaging. 2020;20:12. [PMID: 32000852 DOI: 10.1186/s40644-020-0288-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
45 Indolfi L, Ligorio M, Ting DT, Xega K, Tzafriri AR, Bersani F, Aceto N, Thapar V, Fuchs BC, Deshpande V, Baker AB, Ferrone CR, Haber DA, Langer R, Clark JW, Edelman ER. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma. Biomaterials 2016;93:71-82. [PMID: 27082874 DOI: 10.1016/j.biomaterials.2016.03.044] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
46 Groot VP, Blair AB, Gemenetzis G, Ding D, Burkhart RA, Yu J, Borel Rinkes IH, Molenaar IQ, Cameron JL, Weiss MJ, Wolfgang CL, He J. Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. European Journal of Surgical Oncology 2019;45:1674-83. [DOI: 10.1016/j.ejso.2019.04.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
47 Blair AB, Sorber R, Rozich NS, Burkhart RA. A Qualitative Review of Neoadjuvant Chemotherapy in Resectable Pancreatic Adenocarcinoma. Pancreas 2019;48:973-84. [DOI: 10.1097/mpa.0000000000001376] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
48 Versteijne E, Vogel JA, Besselink MG, Busch ORC, Wilmink JW, Daams JG, van Eijck CHJ, Groot Koerkamp B, Rasch CRN, van Tienhoven G;  Dutch Pancreatic Cancer Group. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 2018;105:946-958. [PMID: 29708592 DOI: 10.1002/bjs.10870] [Cited by in Crossref: 168] [Cited by in F6Publishing: 154] [Article Influence: 42.0] [Reference Citation Analysis]
49 Wang LS, Shaikh T, Handorf EA, Hoffman JP, Cohen SJ, Meyer JE. Dose escalation with a vessel boost in pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Pract Radiat Oncol 2015;5:e457-63. [PMID: 26077273 DOI: 10.1016/j.prro.2015.04.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
50 Malleo G, Maggino L, Ferrone CR, Marchegiani G, Luchini C, Mino-Kenudson M, Paiella S, Qadan M, Scarpa A, Lillemoe KD, Bassi C, Fernàndez-Del Castillo C, Salvia R. Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol 2020;27:3898-912. [PMID: 32307617 DOI: 10.1245/s10434-020-08354-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
51 Hue JJ, Sugumar K, Bingmer K, Ammori JB, Winter JM, Hardacre JM. Neoadjuvant chemoradiation may be associated with improved pathologic response in pancreatic cancer. Am J Surg 2021;221:500-4. [PMID: 33234234 DOI: 10.1016/j.amjsurg.2020.11.035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
52 Xu JZ, Wang WQ, Zhang SR, Xu HX, Wu CT, Qi ZH, Gao HL, Li S, Ni QX, Yu XJ, Liu L. Neoadjuvant Therapy is Essential for Resectable Pancreatic Cancer. Curr Med Chem. 2019;26:7196-7211. [PMID: 29651946 DOI: 10.2174/0929867325666180413101722] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
53 Hartwig W, Gluth A, Hinz U, Koliogiannis D, Strobel O, Hackert T, Werner J, Büchler MW. Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer. British Journal of Surgery 2016;103:1683-94. [DOI: 10.1002/bjs.10221] [Cited by in Crossref: 88] [Cited by in F6Publishing: 73] [Article Influence: 14.7] [Reference Citation Analysis]
54 Lee YS, Lee JC, Yang SY, Kim J, Hwang JH. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and meta-analysis. Sci Rep 2019;9:15662. [PMID: 31666626 DOI: 10.1038/s41598-019-52167-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
55 Buanes TA. Updated therapeutic outcome for patients with periampullary and pancreatic cancer related to recent translational research. World J Gastroenterol 2016; 22(48): 10502-10511 [PMID: 28082802 DOI: 10.3748/wjg.v22.i48.10502] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
56 Kizy S, Altman AM, Wirth KM, Marmor S, Hui JYC, Tuttle TM, Lou E, Amin K, Denbo JW, Jensen EH. Systemic therapy without radiation may be appropriate as neoadjuvant therapy for localized pancreas cancer. Hepatobiliary Surg Nutr 2020;9:296-303. [PMID: 32509815 DOI: 10.21037/hbsn.2019.04.17] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 Nipp RD, Zanconato A, Zheng H, Ferrone CR, Lillemoe KD, Wo JY, Hong TS, Clark JW, Ryan DP, Fernández-del Castillo C. Predictors of Early Mortality After Surgical Resection of Pancreatic Adenocarcinoma in the Era of Neoadjuvant Treatment. Pancreas 2017;46:183-9. [DOI: 10.1097/mpa.0000000000000731] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
58 Chatterjee D, Katz MH, Foo WC, Sundar M, Wang H, Varadhachary GR, Wolff RA, Lee JE, Maitra A, Fleming JB, Rashid A, Wang H. Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy. Am J Surg Pathol 2017;41:1097-104. [PMID: 28614206 DOI: 10.1097/PAS.0000000000000887] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 6.6] [Reference Citation Analysis]
59 Rawicz-Pruszyński K, Ciseł B, Mlak R, Mielko J, Skórzewska M, Kwietniewska M, Pikuła A, Gęca K, Sędłak K, Kurylcio A, Polkowski WP. The Role of the Lymph Node Ratio in Advanced Gastric Cancer After Neoadjuvant Chemotherapy. Cancers (Basel) 2019;11:E1914. [PMID: 31805755 DOI: 10.3390/cancers11121914] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
60 Wittmann D, Hall WA, Christians KK, Barnes CA, Jariwalla NR, Aldakkak M, Clarke CN, George B, Ritch PS, Riese M, Khan AH, Kulkarni N, Evans J, Erickson BA, Evans DB, Tsai S. Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. Front Oncol 2020;10:460. [PMID: 32351886 DOI: 10.3389/fonc.2020.00460] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
61 Schorn S, Demir IE, Haller B, Scheufele F, Reyes CM, Tieftrunk E, Sargut M, Goess R, Friess H, Ceyhan GO. The influence of neural invasion on survival and tumor recurrence in pancreatic ductal adenocarcinoma - A systematic review and meta-analysis. Surg Oncol 2017;26:105-15. [PMID: 28317579 DOI: 10.1016/j.suronc.2017.01.007] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 9.0] [Reference Citation Analysis]
62 Kubo H, Hiroshima Y, Mori R, Saigusa Y, Murakami T, Yabushita Y, Sawada Y, Homma Y, Kumamoto T, Matsuyama R, Endo I. MiR-194-5p in Pancreatic Ductal Adenocarcinoma Peritoneal Washings is Associated with Peritoneal Recurrence and Overall Survival in Peritoneal Cytology-Negative Patients. Ann Surg Oncol 2019;26:4506-14. [PMID: 31489551 DOI: 10.1245/s10434-019-07793-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
63 Pai RK, Pai RK. Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy. Mod Pathol 2018;31:4-23. [DOI: 10.1038/modpathol.2017.87] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
64 Kim SH, Hwang HK, Lee WJ, Kang CM. Identification of an N staging system that predicts oncologic outcome in resected left-sided pancreatic cancer. Medicine (Baltimore) 2016;95:e4035. [PMID: 27368029 DOI: 10.1097/MD.0000000000004035] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
65 Nurmi A, Mustonen H, Parviainen H, Peltola K, Haglund C, Seppänen H. Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer. Acta Oncol 2018;57:799-806. [PMID: 29241394 DOI: 10.1080/0284186X.2017.1415458] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.6] [Reference Citation Analysis]
66 Fischer LK, Katz MH, Lee SM, Liu L, Wang H, Varadhachary GR, Wolff RA, Lee JE, Maitra A, Roland CL, Fleming JB, Estrella J, Rashid A, Wang H. The number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomy. Histopathology 2016;68:210-20. [PMID: 25945396 DOI: 10.1111/his.12732] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
67 Rosumeck N, Timmermann L, Klein F, Bahra M, Stintzig S, Malinka T, Pelzer U. Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma-Who Will Benefit from a Secondary Resection? Medicina (Kaunas) 2021;57:77. [PMID: 33477505 DOI: 10.3390/medicina57010077] [Reference Citation Analysis]